The goals of this study is to identify and validate recently discovered and novel biomarkers of pathophysiology, diagnosis, classification, disease activity, prognosis, treatment susceptibility, and treatment efficacy in IMIDs.
ID
Source
Brief title
Condition
- Autoimmune disorders
- Joint disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
is to identify immunological alterations in the PB and SF of patients with
various forms of inflammatory arthritis and systemic inflammatory diseases and
to correlate these alterations with diagnosis, disease stage, prognosis, and
treatment response. We thereby aim to identify and validate novel biomarkers
that can be used fro personalized medicine in IMIDs
Secondary outcome
N.A.
Background summary
Despite the impact of the immune-mediated inflammatory diseases, the cellular
and molecular pathways (the immunotype) driving these diseases remain largely
unknown. Accordingly, it remains difficult to correctly diagnose and classify
these diseases at an early stage and to predict the persistence and evolution
of the disease in an individual patient. Moreover, despite the development of a
variety of novel and powerful drugs (including the so-called biologicals), the
patient*s response to treatment remains heterogeneous and difficult to predict.
Therefore, there is a clear need for the identification and validation of
cellular and molecular biomarkers which reflect directly the immunotype of a
given disease and can provide useful clinical information for diagnosis,
classification, prognosis and treatment, as well as the development of new
therapeutic strategies.
Study objective
The goals of this study is to identify and validate recently discovered and
novel biomarkers of pathophysiology, diagnosis, classification, disease
activity, prognosis, treatment susceptibility, and treatment efficacy in IMIDs.
Study design
A multicenter study will be started in patients with IMIDs. Patients will be
recruited from the outpatient clinic in AMC, Reade, Flevo and Slotervaart
hopsital and concerns a single visit study. Demographic data and clinical data
regarding classification of diagnosis, medication use and disease activity will
be collected. The synovial fluid will be collected and blood will be drawn once
the patient has given informed consent.
Study burden and risks
Blood drawing has no risks except for hematomas.
Synovial fluid aspiration is done as a regular treatment for arthritis and
therefore no extra risks are involved for this research.
Meibergdreef 9
Amsterdam 1105 AZ
NL
Meibergdreef 9
Amsterdam 1105 AZ
NL
Listed location countries
Age
Inclusion criteria
- patients with an immune-mediated disease (e.g. systemic lupus, rheumatoid arthritis, gout)
- patients of at least 18 years old
Exclusion criteria
- patients who are unable to give informed consent
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| Other | MEC 03/123, geen ABR nr aanwezig, gestart in 2003 |
| CCMO | NL44031.018.13 |